Clinical and economic evaluation of using granulocyte colony-stimulating factor after autologous peripheral blood progenitor cell transplantation in children [1]

Haematologica

Volumn 87, Issue 1, 2002, Pages 105-106

  González Vicent, Marta ^a   Madero, Luis ^a   Sevilla, Julián ^a   Díaz, Miguel Angel ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Children; Cost analysis; G CSF post infusion; PBPCT

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AUTOTRANSPLANTATION; CHILD; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LETTER; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT CARE; SOLID TUMOR; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL COSTS; HUMANS; INFANT; INFECTION CONTROL; LEUKOCYTE COUNT; LIFE TABLES; MALE; NEOPLASMS; NEUTROPENIA; NEUTROPHILS; PLATELET TRANSFUSION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036154508     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Collection and transplantation of peripheral blood progenitor cells mobilized by G-CSF alone in children with malignancies
2. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies
3. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation
4. The role of cytokines following bone marrow transplantation: Indications and controversies
5. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: Evidence for clinical benefits and reduction of treatment costs
6. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit
7. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: Results of a prospective randomized trial
8. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
9. Impact of pharmacy practices on the cost of colony-stimulating factor use in pediatric stem cell transplantation: An institution-based analysis
10. Myelopoietic growth factors after stem cell transplantation: Does it pay